Combination of CT and Ultrasound Radiomics Combined With Liquid Biopsy to Predict Neoadjuvant Che… (NCT07697079) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Combination of CT and Ultrasound Radiomics Combined With Liquid Biopsy to Predict Neoadjuvant Chemotherapy Response in Patients With Locally Advanced Gastric Cancer
China300 participantsStarted 2027-02-01
Plain-language summary
This prospective cohort study aims to construct an artificial intelligence (AI)-derived predictive model for neoadjuvant chemotherapy response prediction in patients with locally advanced gastric cancer based on preoperative ultrasound (US), computed tomography (CT) images and liquid biopsy. Additionally, we explore the potential biological mechanisms behind this model.
Who can participate
Age range
18 Years – 80 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Capable of understanding the study and voluntarily signing the written informed consent form (ICF) prior to any study-specified research procedures.
. Aged ≥18 and ≤80 years old at the time of ICF signing.
. Pathologically confirmed locally advanced gastric cancer (LAGC, cT2NxM0-cT4NxM0) with clinical indications for neoadjuvant chemotherapy.
. Completion of gastrointestinal contrast-enhanced ultrasound and contrast-enhanced abdominal CT before neoadjuvant chemotherapy.
. Provision of peripheral blood samples before chemotherapy (for genetic and protein detection).
. Availability of postoperative pathological specimens for TRG grading after standardized neoadjuvant chemotherapy.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Accuracy of pathological response to neoadjuvant chemotherapyin patients with locally advanced gastric cancer models
Timeframe: The pathological response prediction model will be assessed immediately after its development.
. Willing and able to comply with all study protocol requirements.
Exclusion criteria
. Diagnosis of non-primary gastric cancer.
. Incomplete imaging data, failure to collect peripheral blood samples, or substandard sample quality.
. Discontinued chemotherapy, modified treatment regimen, or lack of complete postoperative pathological assessment.
. Unavailable follow-up data precluding evaluation of chemotherapy response.
. Concurrent participation in another clinical trial; or any other conditions judged by investigators to warrant subject withdrawal, including severe comorbidities requiring simultaneous treatment (psychiatric disorders included), alcohol dependence, substance abuse, or familial/social factors that may compromise subject safety or treatment compliance.